FAKTOR-OPTIONSSCHEIN - GENMAB | Real-time Bid/Ask 18:12:50 03/06/2024 BST | ||
| 11.57 EUR / 12.09 EUR | -3.19% |
|
| 1 month | +6.35% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 03/06/24 | 11.7 | -4.26% |
| 31/05/24 | 12.22 | -2.32% |
| 30/05/24 | 12.51 | -6.01% |
| 29/05/24 | 13.31 | +11.47% |
| 28/05/24 | 11.94 | +3.38% |
Delayed Quote Börse Stuttgart
Last update June 03, 2024 at 05:45 pm
More quotesStatic data
| Product type | Warrant Esotici e Strutturati |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | Morgan Stanley |
| WKN | MG1KCH |
| ISIN | DE000MG1KCH5 |
| Date issued | 03/04/2024 |
| Strike | 2,260 kr |
| Maturity | Unlimited |
| Parity | 3.49 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.54 € |
|---|---|
| Lowest since issue | 9.13 € |
| Spread | 0.52 € |
| Spread % | 4.27% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,937
DKK
Average target price
2,464
DKK
Spread / Average Target
+27.21%
- Stock Market
- Certificates
- Certificat
